A new study from Augusta University’s Medical College in Georgia linked high-dose CBD to multiple benefits associated with familial Alzheimer’s disease, which started earlier, including improved cognition and restoration of the protein responsible for clearing proteins. memorial plaque from the brain. In addition, the CBD has been found to reduce levels of a protein associated with the excessive inflammation that occurs in Alzheimer’s patients.
Alzheimer’s disease is a growing public health issue that is expected to become a major problem as the world population ages. The disease is associated with the buildup of beta-amyloid plaques and other ‘debris’ in patients’ brains, which may be due to a variety of genetics, lifestyle factors and more.
Two proteins in particular play a key role in clearing the brain of the plaque and dead cells; they are called IL-33 and TREM2, both of which occur at lower levels in the case of Alzheimer’s disease. The new study found that high-dose SSK could potentially normalize the level of IL-33 proteins in the brains of Alzheimer’s patients, while reducing the levels of the inflammation-promoting IL-6 protein.
In addition, the CBD has been linked to benefits associated with TREM2, which occurs in lower levels in Alzheimer’s patients. Overall, the CBD protocol was linked to a seven-fold and ten-fold increase in IL-33 and TREM2 protein levels – at least in mice. In addition, the mice were found to show improvement in their motility when given downtown.
More research is needed, including work to determine the ideal dose and evaluate the effect on CBD if it occurs earlier in the earlier stages of Alzheimer’s disease. The findings pave the way for a potential future new treatment for Alzheimer’s disease that could help address the underlying changes leading to the development of the disease.